tbuckley/cabot-search huggingface dataset:
LEUKAEMIA IN PATIENTS TREATED WITH GROWTH HORMONE
Authors: Shaw Watanabe, Yukiko Tsunematsu, Junichiro Fujimoto, Atsushi Komiyama, H.A. Delemaare-van de Waal, R.J.H. Odink, T.J. De Grauw, F.C. De Waal, DelbertA. Fisher, Jean-Claude Job, Michael Preece, Louisee. Underwood
Journal: The Lancet (1988)
Ras Reduces L-Type Calcium Channel Current in Cardiac Myocytes
Authors: Peter D. Ho, Jing-Song Fan, Nicole L. Hayes, Nehad Saada, Philip T. Palade, Christopher C. Glembotski, Patrick M. McDonough
Journal: Circulation Research (2001)

Abstract —Heart failure is associated with dysregulation of intracellular calcium ([Ca 2+ ] i ), reduction in myofibrils, and increased activation of Ras, a regulator of signal-transduction pathways. To evaluate the potential effects of Ras on [Ca 2+ ] i , we expressed constitutively active Ras (Ha-Ras V12 ) in cardiac myocytes and monitored [Ca 2+ ] i via fluorescence and electrophysiological techniques. Ha-Ras V12 reduced the magnitude of the contractile calcium transients. Unexpectedly, however, calcium loading of the sarcoplasmic reticulum was increased, suggesting that Ha-Ras V12 introduces a defect in excitation-calcium release coupling. Consistent with this idea, L-channel calcium currents were reduced by Ha-Ras V12 , which also downregulated the activity of the L-channel gene promoter. Coexpression of L-channels and SERCA2 largely corrected Ha-Ras V12 –induced dysregulation of [Ca 2+ ] i . Furthermore, whereas Ha-Ras V12 downregulated myofibrils, this effect was blocked by coexpression of L-channels. These results suggest that Ras downregulates L-channel expression, which may play a pathophysiological role in cardiac disease.
Are autoantibodies to RNA-polymerase III to be incorporated in routine diagnostic laboratory algorithms for systemic autoimmune rheumatic diseases?
Authors: Jan Damoiseaux
Journal: Annals of the Rheumatic Diseases (2014)

Recently a collaborative initiative of the American College of Rheumatology and the European League against Rheumatism resulted in novel classification criteria for systemic sclerosis (SSc).1 These criteria were first selected in a derivation cohort and, next, confirmed in a validation cohort. From a laboratory perspective it is interesting that the new criteria include, besides the classical anticentromere and antitopoisomerase I antibodies, also the anti-RNA polymerase III antibodies (ARA). These ARA have been associated with diffuse cutaneous involvement and …
A monoclonal antibody (8H3) that binds to rat T lineage cells and augments in vitro proliferative responses.
Authors: Y Torimoto, M Kinebuchi, A Matsuura, K Kikuchi, T Uede
Journal: The Journal of Experimental Medicine (1990)

A murine monoclonal antibody, designated 8H3, recognizes a cell surface antigen expressed exclusively on rat T lineage cells. 8H3 antibody immunoprecipitated 180-, 120-, and 90-kD components from rat thymocytes as well as splenic T cells under nonreducing conditions. 8H3 antibody specifically inhibited the binding of thymocytes to fibronectin. Furthermore, binding of rat thymocytes to immobilized synthetic peptide Gly-Arg-Gly-Asp-Ser-Pro-Cys-BSA was inhibited by 8H3 antibody as was Gly-Arg-Gly-Asp-Ser-Pro-Cys, but not by Gly-Arg-Ala-Asp-Ser-Pro-Lys or Gly-Arg-Gly-Glu-Ser-Pro. Crosslinking of 8H3 antigen on double-negative thymocytes and adult thymocytes, as well as splenic T lymphocytes by 8H3 antibody and F(ab')2 fragments of goat antibodies to mouse immunoglobulin, led to an increase in the concentration of cytoplasmic free Ca2+ due to the release of Ca2+ from intracellular stores as well as the influx of Ca2+ from extracellular sources. Expression of interleukin 2 receptor and subsequently cell proliferation was observed upon incubation of thymocytes and splenic T cells with 8H3 antibody. Furthermore, 8H3 antibody induced the proliferation of double-negative thymocytes. These data collectively indicated that a cell surface antigen, 8H3, is involved in not only cell adhesion but also involved in the expression of immature as well as mature thymocytes.
Increasing prevalence of wheeze and asthma in Nottingham primary schoolchildren 1988-1995
Authors: A Venn, S Lewis, M Cooper, J Hill, J Britton
Journal: European Respiratory Journal (1998)

The prevalence of asthma in children has increased substantially in many countries in recent decades, but it is not clear how much this trend has continued into the 1990s. This study aimed to estimate the current prevalence of asthma and wheeze in British primary schoolchildren and to determine whether there has been any increase in the prevalence of these conditions since 1988. The prevalence of self-reported wheeze and asthma was measured by parental questionnaire in 22,968 children aged 4-11 yrs attending primary schools in the Nottingham area of England in 1995, and these estimates were compared with data from a subsample of the same schools in 1988. In 1995, wheezing ever was reported in 24.0% of children, wheezing in the past year in 15.1% and diagnosed asthma symptomatic in the past year in 8.8%. All measures have increased in prevalence since 1988, in absolute terms by 7.7% for wheeze ever, by 2.6% for wheeze in the past year and by 2.7% for asthma. The increases were greater in females than males, but did not vary with age. In conclusion, the prevalence of asthma has continued to rise in British schoolchildren since the late 1980s, particularly in females, and across all ages.
MiRNA-21: a key to controlling the cardiac fibroblast compartment?
Authors: A. Haghikia, D. Hilfiker-Kleiner
Journal: Cardiovascular Research (2009)

This editorial refers to 'MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue' by S. Roy et al.,4 pp.21-29, this issue.Myocardial ischaemia is a condition in which the coronary blood flow to the heart is reduced, which results in deficient oxygen and nutrients supply to the heart.In the clinical setting, reperfusion of the ischaemic heart is achieved by primary angioplasty, a process that, if induced early, rescues a large portion of the ischaemic myocardium.However, this is often obscured by adverse processes such as myocardial stunning injury and cardiac remodelling, i.e. ventricular hypertrophy, interstitial fibrosis, contractile dysfunction, inflammation, and chamber dilatation. 1 Both cardiomyocytes and non-myocytes are affected, and at the molecular level, multiple extra-and intracellular signalling systems are involved, orchestrating a multitude of factors that determine the final phenotypic manifestation of the injury and the disease prognosis. 2In the acute phase of myocardial ischaemia-reperfusion (I/R), activation of matrix metalloproteinases (MMPs) allows degradation of fibrillar collagen and cleavage of the basement membrane surrounding necrotic myocytes-a prerequisite for the invasion and proliferation of cells, e.g.fibroblasts, inflammatory, and vascular cells-ensuring tissue repair and scar formation. 3t is of major interest for the clinical arena to understand these processes in order to identify novel therapeutic targets for the prevention of ventricular injury and maladaptive remodelling and dysfunction in response to I/R.In this regard, the study by Roy et al. 4 opens a novel aspect by demonstrating that microRNA-21 (miR-21) is upregulated in cardiac fibroblasts after I/R injury and there plays potentially important roles in regulating major signalling pathways and their downstream effectors.MicroRNAs (miRNAs) are short regulatory RNAs that act as negative regulators of gene expression by inhibiting mRNA translation or by promoting mRNA degradation. 5It is estimated that more than 1000 miRNAs are encoded by the human genome, and evidence shows that many are
Biological and Clinical Implications of Lymphocyte Hybridomas: Tumor Therapy with Monoclonal Antibodies
Authors: R Levy, R A Miller
Journal: Annual Review of Medicine (1983)

Monoclonal antibodies of defined specificity can be produced using hybridoma technology. New attempts are being made to explore the potential of antibody therapy for cancer. Preliminary studies show that problems such as antigenic modulation, circulating free antigen, effector cell shortage, and host anti-mouse immunoglobulin response must be overcome. Uses of monoclonal antibodies in cancer treatment include the administration of unconjugated antibodies or of antibodies coupled to drugs, toxins, or radioisotopes, and the use of monoclonal antibodies in vitro to eradicate residual malignant cells.
Acute dyspnoea and single tracheal localisation of mantle cell lymphoma
Authors: Jean-Christophe Ianotto, Adrian Tempescul, Jean-Richard Eveillard, Norbert André, Frederic Morel, Isabelle Quintin-Roué, Christian Berthou
Journal: Journal of Hematology & Oncology (2010)

Mantle cell lymphoma is a lymphoid entity characterized by adenopathy, blood and bone marrow involment which only recurrent mucosal localisation is the lymphomatoid polyposis. Few other mucosal infiltrations have been already reported. We report here the first case of a unique tracheal localisation of mantle cell lymphoma at presentation of the disease. The presence of classical t(11;14)(q13;q32) confirmed the diagnosis of mantle cell lymphoma by eliminating MALT or cancer localisation. This case illustrates the necessity to ensure the diagnosis of mucosal lymphoma versus MCL since these diseases need different treatment regimens and prognoses.
Survival Data From a Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy in Patients With Advanced and Recurrent Cervical Cancer
Authors: Bradley J. Monk, Lini N. Pandite
Journal: Journal of Clinical Oncology (2011)

Journal of ClinicalOncology, we reported the primary end point of progression-free survival (PFS) along with immature overall survival (OS) data for pazopanib versus lapatinib in patients with metastatic recurrent cervical carcinoma. 1At the time of publication, we reported a planned interim analysis of OS, performed at the time of the primary PFS analysis.Forty-two percent of patients in the lapatinib group and 61% of patients in the pazopanib group were still alive and were thus censored for the analysis, as shown in Figure 2B of our article. 1Median OS at this clinical cutoff date was 11.6 weeks longer in the pazopanib arm compared with the lapatinib arm (median OS, 50.7 weeks v 39.1 weeks; hazard ratio, 0.67; 90% CI, 0.46 to 0.99; P ϭ .045).The final OS analysis was performed when 62 patients (79.5%) in the lapatinib group and 56 patients (75.7%) in the pazopanib group had died.The median OS was 44.1 weeks for patients who received lapatinib and 49.7 weeks for patients who received pazopanib (hazard ratio, 0.96; 90% CI, 0.71 to 1.30; P ϭ .407;Fig 1).Importantly, the study was not powered for OS.This study met its primary end point of demonstrating an improvement in PFS with pazopanib compared with lapatinib.The updated data may be helpful to clinicians designing clinical trials of pazopanib in cervical cancer.
Flexor hallucis longus muscle atrophy due to a chronic compartment syndrome of the lower leg.
Authors: M Lehto, V Rantakokko, M Kormano, M Järvinen
Journal: British Journal of Sports Medicine (1988)

LOWER LEGWe would like to report a case of chronic compartment syndrome in a long distance runner.The leg has four compartments -anterior, lateral, superficial and deep posterior -which are prone to produce ischaemic damage to muscle and nerves when intractable swelling is present.The clinical picture of the acute compartment syndrome comprises symptoms such of pain, pallor, paresthesia, pulselessness and finally, paralysis.The syndrome in its chronic form is seen in long distance runners and other endurance athletes and it differs
The Lettsomian Lectures on Syphilis and the Nervous System
Authors: W. R. Gowers
Journal: BMJ (1889)

A GENEIAL survey of the treatment of syphilis, as well as the observation of individual cases, can scarcely fail to impress one important conclusion on an impartial observer.It is not easy to state this conclusion in language not open to misconstruction.Stated in its baldest form, the conclusion is that syphilis is an incurable disease.Stated in the form least liable to misinterpre- tation, and with the limits of exactness, it is this: there is no real evidence that the disease ever is or ever has been cured, the word disease being used here to designate that which causes the various manifestations of the malady.The statement that " syphilis is an incurable disease " is the shortest way of stating this fact, and it is legitimate if we recognise that " by incurable " merely we mean that there is no proof of cure.I do not put this opinion forward as in any way novel; indeed, I feel with regret that on this and on many other points in these lectures, I express opinions that are held by others, some of which have been well stated by others, and all of which, I cannot doubt, have been stated more than once.I regret that it has not been possible for me to ascertain the extent to which this and other opinions have been before expressed: hence, I feel that the only course that is just to others and safe for myself is to ask you to regard nothing in these lectures as having any claim to originality.As I said at the outset, my desire is to render more definite the knowledge that already exists, and not to bring new knowledge into exi6tence.In current works on syphilis the fact of ineurability is clearly recognised, although even in these it is not quite compatible with the language here and there employed.But the fact is cer- tainly not accepted by the profession at large in the manner which seems to me to be warranted by the facts.It is, 1 think, most important for practical reasons that it should be understood by all, that, as far as evidence at present goes-whatever power we may hope and anticipate that the future will bring-no treatment, hlowever thorough, will bring the disease to an end, so that the
AUTOMATED 3-D QUANTIFICATION OF LEFT VENTRICULAR VOLUMES AND EJECTION FRACTION IN ATRIAL FIBRILLATION BY TRANSTHORACIC REAL-TIME VOLUME IMAGING
Authors: Shizhen Liu, Bogdan Georgescu, Adrien Nitnunu, Thomas Van Houten, Helene Houle, Nathalie De Michelis, Anna Calleja, Mary Ellen Orsinelli, Peng Li, Paaladinesh Thavendiranathan, Thomas Ryan, Mani Vannan
Journal: Journal of the American College of Cardiology (2010)
Effects of partial neuromuscular blockade on sympathetic nerve responses to static exercise in humans.
Authors: R G Victor, S L Pryor, N H Secher, J H Mitchell
Journal: Circulation Research (1989)

We used intraneural recordings of sympathetic nerve activity in conscious humans to determine if central command increases sympathetic discharge to resting skeletal muscle during static exercise. In nine healthy subjects, we measured arterial pressure, heart rate, and muscle sympathetic nerve activity with microelectrodes in the peroneal nerve of the resting leg during 1) static handgrip at 15% and 30% maximal voluntary contraction and 2) attempted handgrip during partial neuromuscular blockade produced by systemic administration of tubocurarine chloride (0.075 mg/kg i.v.). During curare, subjects reported that they used near-maximal motor effort to attempt a sustained handgrip contraction, but they generated almost no force. Without sustained contraction, the intent to exercise alone, that is, central command, caused statistically significant (p less than 0.05) increases in muscle sympathetic nerve activity as well as in arterial pressure and heart rate. However, the increases in muscle sympathetic nerve activity (+ 56 +/- 16% over control) and in mean arterial pressure (+ 12 +/- 2 mm Hg) during attempted handgrip were much smaller (p less than 0.05) than the sympathetic nerve response (+ 217 +/- 37% over control) and pressor response (+ 25 +/- 3 mm Hg) during an actual static handgrip at 30% maximal voluntary contraction. In contrast, heart rate increased as much during the attempted contraction (+ 18 +/- 2 beats/min) as during the actual contraction at 30% maximal voluntary contraction (+ 16 +/- 4 beats/min). In 11 additional subjects, the heart rate responses during curare were greatly attenuated (p less than 0.05) by atropine but were not significantly affected by propranolol.(ABSTRACT TRUNCATED AT 250 WORDS)
p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas
Authors: K. Leroy, C. Haioun, E. Lepage, N. Le Métayer, F. Berger, E. Labouyrie, V. Meignin, B. Petit, C. Bastard, G. Salles, C. Gisselbrecht, F. Reyes, Ph. Gaulard
Journal: Annals of Oncology (2002)
A Syndrome Featuring Defects of the Heart, Sternum, Diaphragm, and Anterior Abdominal Wall
Authors: I. HUNTER CRITTENDEN, FORREST H. ADAMS, DONALD G. MULDER
Journal: Circulation (1959)

Three patients featuring a syndrome of defects of the heart, sternum, diaphragm, and anterior abdominal wall are presented. The striking similarity of the anomalies manifested by the 3 cases posed a question whether or not a recognized syndrome previously existed. In order to determine this, a search was made to find other such cases, and an attempt was made to establish a common embryologic pathogenesis. Review of the literature as well as extensive personal communication was carried out. Embryology of the involved organs was considered in order to determine a specific phase of defective development.
P243 Are healthcare professionals aware of costs of respiratory inhalers?: Abstract P243 Table 1
Authors: V Mak, H Marlow, L Restrick, A Porter
Journal: Thorax (2012)

<h3>Introduction</h3> In 2011, 3 of the top 5 most expensive drugs to the NHS were respiratory inhalers, the most expensive being Seretide 250 evohaler. To achieve best value from our respiratory spend, healthcare professionals (HCPs) should know the relative costs of inhalers, and that their patients are using these devices appropriately. We undertook a survey of HCPs to test their knowledge of respiratory inhaler cost and how well the devices are used. <h3>Methods</h3> We created a Survey Monkey questionnaire concerning the costs of commonly prescribed respiratory inhalers (see table) allowing respondents to click on an approximate range of costs for one month’s treatment at normal recommended dose. We also asked about awareness of the evidence for effective use of metered dose inhalers (MDIs) by patients and HCPs. The survey was disseminated by email from various databases in community and hospital care within NHS London and beyond, especially to those involved in respiratory care. <h3>Results</h3> There were 1274 respondents, 21% were doctors, 38% nurses, 21% pharmacists and 15% allied healthcare professionals (AHPs), 70% had a respiratory interest and 89% were clinicians. Overall, the correct price range was identified by fewer than 50% of all respondents for the inhalers tested (except generic salbutamol), the worst being for Seretide 250 evohaler and Ventol in evohaler (see table). 76% of respondents were not aware that fewer than 10% of patients can use an MDI effectively and 87% were not aware that fewer than 10% of HCPs can demonstrate the correct use of an MDI. Having attended a London Respiratory Team (LRT) event significantly improved the correct response rate (see table). <h3>Conclusions</h3> Most HCPs are not aware of the costs of inhalers and how poorly some inhalers are used. Increasing awareness of cost could add a sense of value and improve responsible prescribing, including renewed focus on stepping down patients on high potency treatments when they are stable or have experienced no benefit, and always using a spacer with an MDI. Knowledge of which inhalers provide best value is also important for prescribers when choosing between evidenced based alternatives.
The Patient-Provider Relationship: Attachment Theory and Adherence to Treatment in Diabetes
Authors: Paul S. Ciechanowski, Wayne J. Katon, Joan E. Russo, Edward A. Walker
Journal: American Journal of Psychiatry (2001)

OBJECTIVE: Lack of adherence to diabetic self-management regimens is associated with a high risk of diabetes complications. Previous research has shown that the quality of the patient-provider relationship is associated with adherence to diabetes treatment. This study attempts to improve understanding of both patient and provider factors involved in lack of adherence to treatment in diabetic patients by using the conceptual model of attachment theory. METHOD: Instruments that assessed attachment, treatment adherence, depression, diabetes severity, patient-provider communication, and demographic data were administered to 367 patients with type 1 and 2 diabetes in a health maintenance organization primary care setting. Glucose control, medical comorbidity, and adherence to medications and clinic appointments were determined from automated data. Analyses of covariance were used to determine if attachment style and quality of patient-provider communication were associated with adherence to treatment. RESULTS: Patients who exhibited dismissing attachment had significantly worse glucose control than patients with preoccupied or secure attachment. An interaction between attachment and communication quality was significantly associated with glycosylated hemoglobin (Hb A1c) levels. Among the patients with a dismissing attachment style, there was a significant difference in glycosylated hemoglobin levels between those who rated their patient-provider communication as poor (mean=8.50%, SD=1.55%) and those who rated this communication as good (mean=7.49%, SD=1.33%). Among all patients who were taking oral hypoglycemics, adherence to medications and glucose monitoring was significantly worse in patients who exhibited dismissing attachment and rated their patient-provider communication as poor. CONCLUSIONS: Dismissing attachment in the setting of poor patient-provider communication is associated with poorer treatment adherence in patients with diabetes.
EBUS-TBNA in the differential diagnosis of pulmonary artery sarcoma and thromboembolism
Authors: J.S. Park, J-H. Chung, S. Jheon, D-J. Choi, H.I. Yoon, J.H. Lee, C-T. Lee, S.W. Lee
Journal: European Respiratory Journal (2011)

To the Editors:

Pulmonary artery sarcoma is a rare tumour of the cardiovascular system. It is often misdiagnosed as acute or chronic pulmonary thromboembolism because its clinical presentation and radiological findings are similar to those of thromboembolism. The diagnosis of pulmonary artery sarcoma by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has not been reported. Herein, we report two cases with mass-like lesion in the pulmonary artery. The lesions were safely approached by EBUS-TBNA, and the tissues obtained by EBUS-TBNA were sufficient to diagnose pulmonary artery sarcoma and thromboembolism.

A 79-yr-old female with hypertension and atrial fibrillation presented with sudden-onset left chest and shoulder pain. She had taken warfarin for atrial fibrillation, but the warfarin had been discontinued for 1 week because of a scheduled endoscopy. We performed chest computed tomography (CT), which revealed an extensive intraluminal low-attenuated mass- like lesion involving the entire luminal diameter of the left main and left lower lobar pulmonary artery (fig. 1a). d-dimer was 0.94 μg·mL−1 (reference value <0.4 μg·mL−1). Positron emission tomography (PET)-CT with 18F-fluorodeoxyglucose (FDG) showed increased FDG uptake, with a maximum standardised uptake value (SUV max) of 18.6 in the left main pulmonary artery (fig. 1c). For a tissue diagnosis, EBUS-TBNA was performed targeting the mass-like lesion encasing the pulmonary artery (fig. 1d). The sonograph revealed a round heterogeneous mass with distinct margin that include some necrotic area. The cytopathological examination confirmed spindle cell malignancy with vimentin …